Immunemodulation in Patients With Minor Head Injury (MHI)

This study has been completed.
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00622778
First received: February 13, 2008
Last updated: April 10, 2012
Last verified: July 2011
  Purpose

The purpose of this study is to try to prove the worth of the two (2) Serum Proteins S-100 Beta and NSE in combination with a diagnostic algorithm to help to establish diagnosis in patients with minor head injury.


Condition
Head Trauma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diagnostic Algorithm in Minor Head Injury

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Intracranial Haematoma [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum from peripheral blood


Enrollment: 130
Study Start Date: October 2007
Study Completion Date: July 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients from daily practice

  Eligibility

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients from daily practice

Criteria

Inclusion Criteria:

  • minor head injury

Exclusion Criteria:

  • severe head injury
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00622778

Locations
Austria
Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Investigators
Study Chair: Vilmos Vecsei, M.D. Professor Head of Department